Current concepts in anticoagulant therapy

S. C. Litin, D. A. Gastineau

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

An understanding of the international normalized ratio (INR) - which was developed to standardize reporting of the prothrombin time (PT) and provide consistent regulation of anticoagulation - is important. The recommended therapeutic range for the INR (which is calculated from the patient's PT, a mean control PT, and the international sensitivity index) for oral anticoagulant treatment of most conditions is 2.0 to 3.0. In patients with mechanical cardiac valves, the INR should be at least 2.5 to 3.5. A common cause for progression of venous thromboembolic disease and treatment failure is inadequate heparinization during the first day of treatment. Therefore, an intravenous bolus of 5,000 to 10,000 U of heparin should be administered before a maintenance infusion is initiated. Also during the first day of treatment, warfarin therapy can be implemented. Overlap treatment with heparin and warfarin for 4 or 5 days is recommended. Low-molecular-weight heparins, a new class of anticoagulants, have been shown to be more effective than standard heparin in preventing venous thrombosis in orthopedic surgical patients, but at a higher cost. Patients with mechanical cardiac valves who are receiving anticoagulant therapy and are scheduled for noncardiac operations must have a risk-to-benefit assessment of the need for continuous anticoagulation performed preoperatively. Many of these patients can safely discontinue warfarin therapy for several days as outpatients before the surgical procedure. Preoperative heparin therapy and warfarin withdrawal in the hospital are recommended only for those patients with cardiac valves at high risk for systemic embolization (with a mitral valve prosthesis, cardiomyopathy, or previous thromboembolism). The concurrent use of certain drugs or presence of comorbid conditions can predispose to hemorrhagic complications of anticoagulant therapy. Discontinuation of warfarin treatment, administration of vitamin K, or replacement of vitamin K-dependent coagulation factors with transfusion of fresh-frozen plasma will reverse the anticoagulant effects of warfarin.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalMayo Clinic Proceedings
Volume70
Issue number3
StatePublished - 1995

Fingerprint

Anticoagulants
Warfarin
International Normalized Ratio
Heparin
Prothrombin Time
Heart Valves
Therapeutics
Vitamin K
Blood Coagulation Factors
Low Molecular Weight Heparin
Thromboembolism
Treatment Failure
Cardiomyopathies
Mitral Valve
Venous Thrombosis
Prostheses and Implants
Orthopedics
Outpatients
Maintenance
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Litin, S. C., & Gastineau, D. A. (1995). Current concepts in anticoagulant therapy. Mayo Clinic Proceedings, 70(3), 266-272.

Current concepts in anticoagulant therapy. / Litin, S. C.; Gastineau, D. A.

In: Mayo Clinic Proceedings, Vol. 70, No. 3, 1995, p. 266-272.

Research output: Contribution to journalReview article

Litin, SC & Gastineau, DA 1995, 'Current concepts in anticoagulant therapy', Mayo Clinic Proceedings, vol. 70, no. 3, pp. 266-272.
Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clinic Proceedings. 1995;70(3):266-272.
Litin, S. C. ; Gastineau, D. A. / Current concepts in anticoagulant therapy. In: Mayo Clinic Proceedings. 1995 ; Vol. 70, No. 3. pp. 266-272.
@article{6d9a639ac5224c19a4e1eb758415bc88,
title = "Current concepts in anticoagulant therapy",
abstract = "An understanding of the international normalized ratio (INR) - which was developed to standardize reporting of the prothrombin time (PT) and provide consistent regulation of anticoagulation - is important. The recommended therapeutic range for the INR (which is calculated from the patient's PT, a mean control PT, and the international sensitivity index) for oral anticoagulant treatment of most conditions is 2.0 to 3.0. In patients with mechanical cardiac valves, the INR should be at least 2.5 to 3.5. A common cause for progression of venous thromboembolic disease and treatment failure is inadequate heparinization during the first day of treatment. Therefore, an intravenous bolus of 5,000 to 10,000 U of heparin should be administered before a maintenance infusion is initiated. Also during the first day of treatment, warfarin therapy can be implemented. Overlap treatment with heparin and warfarin for 4 or 5 days is recommended. Low-molecular-weight heparins, a new class of anticoagulants, have been shown to be more effective than standard heparin in preventing venous thrombosis in orthopedic surgical patients, but at a higher cost. Patients with mechanical cardiac valves who are receiving anticoagulant therapy and are scheduled for noncardiac operations must have a risk-to-benefit assessment of the need for continuous anticoagulation performed preoperatively. Many of these patients can safely discontinue warfarin therapy for several days as outpatients before the surgical procedure. Preoperative heparin therapy and warfarin withdrawal in the hospital are recommended only for those patients with cardiac valves at high risk for systemic embolization (with a mitral valve prosthesis, cardiomyopathy, or previous thromboembolism). The concurrent use of certain drugs or presence of comorbid conditions can predispose to hemorrhagic complications of anticoagulant therapy. Discontinuation of warfarin treatment, administration of vitamin K, or replacement of vitamin K-dependent coagulation factors with transfusion of fresh-frozen plasma will reverse the anticoagulant effects of warfarin.",
author = "Litin, {S. C.} and Gastineau, {D. A.}",
year = "1995",
language = "English (US)",
volume = "70",
pages = "266--272",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - Current concepts in anticoagulant therapy

AU - Litin, S. C.

AU - Gastineau, D. A.

PY - 1995

Y1 - 1995

N2 - An understanding of the international normalized ratio (INR) - which was developed to standardize reporting of the prothrombin time (PT) and provide consistent regulation of anticoagulation - is important. The recommended therapeutic range for the INR (which is calculated from the patient's PT, a mean control PT, and the international sensitivity index) for oral anticoagulant treatment of most conditions is 2.0 to 3.0. In patients with mechanical cardiac valves, the INR should be at least 2.5 to 3.5. A common cause for progression of venous thromboembolic disease and treatment failure is inadequate heparinization during the first day of treatment. Therefore, an intravenous bolus of 5,000 to 10,000 U of heparin should be administered before a maintenance infusion is initiated. Also during the first day of treatment, warfarin therapy can be implemented. Overlap treatment with heparin and warfarin for 4 or 5 days is recommended. Low-molecular-weight heparins, a new class of anticoagulants, have been shown to be more effective than standard heparin in preventing venous thrombosis in orthopedic surgical patients, but at a higher cost. Patients with mechanical cardiac valves who are receiving anticoagulant therapy and are scheduled for noncardiac operations must have a risk-to-benefit assessment of the need for continuous anticoagulation performed preoperatively. Many of these patients can safely discontinue warfarin therapy for several days as outpatients before the surgical procedure. Preoperative heparin therapy and warfarin withdrawal in the hospital are recommended only for those patients with cardiac valves at high risk for systemic embolization (with a mitral valve prosthesis, cardiomyopathy, or previous thromboembolism). The concurrent use of certain drugs or presence of comorbid conditions can predispose to hemorrhagic complications of anticoagulant therapy. Discontinuation of warfarin treatment, administration of vitamin K, or replacement of vitamin K-dependent coagulation factors with transfusion of fresh-frozen plasma will reverse the anticoagulant effects of warfarin.

AB - An understanding of the international normalized ratio (INR) - which was developed to standardize reporting of the prothrombin time (PT) and provide consistent regulation of anticoagulation - is important. The recommended therapeutic range for the INR (which is calculated from the patient's PT, a mean control PT, and the international sensitivity index) for oral anticoagulant treatment of most conditions is 2.0 to 3.0. In patients with mechanical cardiac valves, the INR should be at least 2.5 to 3.5. A common cause for progression of venous thromboembolic disease and treatment failure is inadequate heparinization during the first day of treatment. Therefore, an intravenous bolus of 5,000 to 10,000 U of heparin should be administered before a maintenance infusion is initiated. Also during the first day of treatment, warfarin therapy can be implemented. Overlap treatment with heparin and warfarin for 4 or 5 days is recommended. Low-molecular-weight heparins, a new class of anticoagulants, have been shown to be more effective than standard heparin in preventing venous thrombosis in orthopedic surgical patients, but at a higher cost. Patients with mechanical cardiac valves who are receiving anticoagulant therapy and are scheduled for noncardiac operations must have a risk-to-benefit assessment of the need for continuous anticoagulation performed preoperatively. Many of these patients can safely discontinue warfarin therapy for several days as outpatients before the surgical procedure. Preoperative heparin therapy and warfarin withdrawal in the hospital are recommended only for those patients with cardiac valves at high risk for systemic embolization (with a mitral valve prosthesis, cardiomyopathy, or previous thromboembolism). The concurrent use of certain drugs or presence of comorbid conditions can predispose to hemorrhagic complications of anticoagulant therapy. Discontinuation of warfarin treatment, administration of vitamin K, or replacement of vitamin K-dependent coagulation factors with transfusion of fresh-frozen plasma will reverse the anticoagulant effects of warfarin.

UR - http://www.scopus.com/inward/record.url?scp=0028922864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028922864&partnerID=8YFLogxK

M3 - Review article

VL - 70

SP - 266

EP - 272

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -